CIK 0000887359 · Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- operating
- EIN
- 943096597
- Phone
- 6175885555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,787,802
- in 7 filings, $5.8M under 10b5-1 plans
Net −$5,787,802. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$79K Principal Accounting Officer sold 54% of stake
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-28 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise 10b5-1 | +3,908 | $48.80 | $191K | 5,114 |
| 2025-01-28 | SIEGAL JONATHAN Principal Accounting Officer | Sale 10b5-1 | −3,908 | $61.99 | $242K | 1,206 |
| 2025-01-28 | SIEGAL JONATHAN Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | +3,908 | 52,967 | ||
| 2024-12-04 | Wotton Paul K Director | Sale | −2,600 | $58.72 | $153K | 27,402 |
| 2024-12-02 | Hopper Jonathan Mark Chief Medical Officer | Option exercise 10b5-1 | +10,000 | $16.66 | $167K | 68,371 |
| 2024-12-02 | Hopper Jonathan Mark Chief Medical Officer | Sale 10b5-1 | −10,000 | $58.72 | $587K | 58,371 |
| 2024-12-02 | Hopper Jonathan Mark Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | +10,000 | 6,000 | ||
| 2024-11-22 | ZERBE ROBERT L MD Director | Option exercise 10b5-1 | +2,500 | $13.05 | $33K | 29,095 |
| 2024-11-22 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $60.00 | $150K | 26,595 |
| 2024-11-22 | ZERBE ROBERT L MD Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +2,500 | 10,000 | ||
| 2024-11-14 | Colangelo Dominick President and CEO | Option exercise 10b5-1 | +17,500 | $3.02 | $53K | 238,437 |
| 2024-11-14 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $53.93 | $944K | 220,937 |
| 2024-11-14 | Colangelo Dominick President and CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | +17,500 | 0 | ||
| 2024-11-13 | MCLAUGHLIN KEVIN F Director | Option exercise 10b5-1 | +7,000 | $3.74 | $26K | 18,900 |
| 2024-11-13 | MCLAUGHLIN KEVIN F Director | Sale 10b5-1 | −7,000 | $55.54 | $389K | 11,900 |
| 2024-11-13 | MCLAUGHLIN KEVIN F Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +7,000 | 6,000 | ||
| 2024-11-13 | Colangelo Dominick President and CEO | Option exercise 10b5-1 | +17,500 | $3.02 | $53K | 238,437 |
| 2024-11-13 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $55.57 | $972K | 220,937 |
| 2024-11-13 | Colangelo Dominick President and CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | +17,500 | 17,500 | ||
| 2024-11-12 | ZERBE ROBERT L MD Director | Option exercise 10b5-1 | +2,500 | $13.05 | $33K | 29,095 |
Page 21 of 75 · 1,497 trades